Triple Agonists (GLP-1/GIP/Glucagon) REMS Programs and Special Handling: What Women Need to Know

What Is a REMS Program and Why Might Triple Agonists Need One?

A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-mandated safety program that goes beyond routine prescribing information when a drug's benefits can only be said to outweigh its risks if specific safeguards are in place. The FDA can require a REMS under the Food and Drug Administration Amendments Act of 2007 when a drug carries risks such as teratogenicity, a narrow therapeutic window, or serious organ toxicity that warrants extra monitoring.

Triple agonists do not yet have an approved REMS because no drug in this class has received FDA approval. Retatrutide, the most clinically advanced triple agonist, is currently in Phase 3 evaluation. Predicting exactly what a future REMS will look like is speculative, but the class shares structural and mechanistic overlap with tirzepatide (a dual GIP/GLP-1 agonist) and semaglutide, neither of which currently carries a REMS. The key unknown is the glucagon receptor arm: higher glucagon activity raises questions about hepatic effects, bone density, and cardiovascular signaling that regulators will scrutinize carefully.

Why Regulators Watch This Class Closely

The glucagon receptor component is what separates triple agonists from their predecessors. Glucagon receptor agonism drives hepatic glucose output and fat oxidation but also stimulates osteoclast activity, a concern for women who already face accelerated bone loss after menopause. In rodent models, chronic glucagon receptor stimulation reduced bone mineral density, though direct human fracture data in this specific class do not yet exist.

Regulators may also scrutinize the class for thyroid C-cell signal. The GLP-1 receptor is expressed on rodent thyroid C-cells, and all GLP-1-based therapies carry an FDA boxed warning about medullary thyroid carcinoma (MTC) risk in rodents. That boxed warning applies to semaglutide and tirzepatide per FDA prescribing information and is expected to carry forward to any approved triple agonist.

Elements a Future REMS Might Include

Based on how the FDA has structured REMS programs for comparable teratogenic or high-risk weight-management drugs (topiramate/phentermine under a REMS, for example), a triple-agonist REMS could require:

• Prescriber enrollment and training on teratogenic risk
• Pharmacy certification before dispensing
• A patient agreement form that documents counseling on contraception
• Pregnancy exposure registry enrollment
• Periodic monitoring labs (liver enzymes, lipase, bone density in long-term users)

Women's health clinicians should anticipate a contraception-centered REMS component as the most likely mandatory element, given the embryotoxicity signals in preclinical data.

Retatrutide Phase 2 Data: What the Numbers Show for Women

The key Phase 2 retatrutide trial published in The New England Journal of Medicine in 2023 enrolled 338 adults with obesity (BMI 30 to 50 kg/m²) or overweight (BMI 27 to 30 kg/m²) with at least one weight-related complication. At 48 weeks, participants on the highest dose (12 mg weekly) lost a mean of 24.2% of their body weight, substantially more than what tirzepatide achieved in its Phase 3 SURMOUNT-1 trial (20.9% at the highest dose) or semaglutide in STEP-1 (14.9%).

The trial was not powered to detect sex-specific differences in efficacy, and women were not analyzed as a separate subgroup in the published results. This is a meaningful evidence gap. Women metabolize GLP-1-class drugs differently from men: lower average body weight means weight-based dosing can produce proportionally higher plasma concentrations, and progesterone fluctuations across the menstrual cycle alter gastric emptying rates, which affects subcutaneously absorbed peptide drugs.

What This Means Across the Menstrual Cycle

During the luteal phase (days 15 to 28 of a typical cycle), progesterone slows gastric motility. GLP-1 receptor agonists already slow gastric emptying independently. The combined effect may intensify nausea, bloating, and early satiety in the second half of the cycle. Women using retatrutide in clinical trials should track their cycle alongside GI side effects; this data would be clinically valuable and is not currently being collected in a standardized way.

MASLD and PCOS: Two Conditions Where Triple Agonists May Be Particularly Relevant

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25% of adults globally, and women with PCOS carry a substantially higher MASLD prevalence than the general female population, with some estimates reaching 30 to 55%. Glucagon receptor agonism drives hepatic fat oxidation directly, which is why researchers are specifically investigating retatrutide for MASLD in a dedicated Phase 3 trial. For women with PCOS who also have hepatic steatosis, this mechanistic overlap is meaningful.

In perimenopause, the combination of falling estrogen, rising visceral adiposity, and worsening insulin resistance creates a metabolic environment where triple agonists could offer multi-target benefit. Estrogen has GLP-1-sensitizing effects at the receptor level; as estrogen falls, the GLP-1 pathway becomes less efficient, which may be why some menopausal women find that GLP-1 monotherapy is less effective for them than it was in their reproductive years. The glucagon and GIP arms of a triple agonist could theoretically compensate for some of this receptor desensitization, though direct data in postmenopausal women do not yet exist.

Special Handling: Storage, Injection, and Medication Safety

Storage Requirements

Retatrutide, like other injectable peptide drugs in this class, requires cold-chain storage. Based on Eli Lilly's published formulation data and precedent from tirzepatide's prescribing information, the expected requirements are:

• Refrigerate at 2°C to 8°C (36°F to 46°F) until first use
• After first use or removal from refrigeration, store at room temperature below 30°C (86°F) for a maximum of 30 days
• Protect from direct light and freezing; frozen pens must be discarded
• Do not use after the expiration date printed on the label

Women managing weight medications alongside hormone therapy injections or insulin should organize a dedicated medication drawer or fridge section to avoid confusion between similarly sized autoinjector pens.

Injection Technique and Site Rotation

Triple agonists are administered subcutaneously, typically once weekly. Proper site rotation reduces the risk of lipodystrophy, localized inflammation, and inconsistent absorption. Recommended rotation sites include the abdomen (at least 2 inches from the navel), the outer thigh, and the upper arm. Rotating systematically, for example using a clockface pattern within each region, prevents repeated trauma to the same tissue.

Women using continuous glucose monitors (CGMs) or insulin pump infusion sets should confirm that their triple-agonist injection site is at least 3 centimeters away from active CGM sensors or pump cannulas to avoid interference with device accuracy or local absorption of either drug.

Dose Escalation Schedule and Why It Matters

The Phase 2 trial used a structured dose escalation starting at 1 mg weekly, increasing through 2 mg, 4 mg, 8 mg, and up to 12 mg weekly at 4 to 8-week intervals. Slower escalation significantly reduced nausea and vomiting rates in the trial. Women who are also managing cyclic GI symptoms (nausea related to high estrogen or progesterone states, or to hormonal IUDs) may find the escalation phase particularly challenging in certain weeks of their cycle. Clinicians should advise patients to escalate doses during the follicular phase when GI tolerance tends to be better.

Pregnancy, Lactation, and Contraception: A Required Discussion

Retatrutide is not safe in pregnancy. This is the single most important safety message for women of reproductive age considering or using this drug.

Pregnancy Data

No human pregnancy data exist for retatrutide. Animal reproductive toxicology studies, which Eli Lilly conducted as part of the IND application process, demonstrated embryotoxicity at doses that produced plasma exposures comparable to clinical doses. The FDA has established that embryo-fetal developmental toxicity in animals is a required regulatory concern that shapes the label's pregnancy warning, even before human data are available. For GLP-1-class drugs broadly, the FDA assigns a warning against use in pregnancy based on this animal data precedent.

Semaglutide's prescribing label states: "Based on animal reproduction studies, semaglutide may cause fetal harm when administered to a pregnant woman". Retatrutide's final label will almost certainly carry equivalent or stronger language given that glucagon receptor agonism adds a separate developmental risk signal not present with semaglutide alone.

Women who become pregnant while on a triple agonist should discontinue the drug immediately and contact their obstetric provider.

Washout Period Before Attempting Conception

Because retatrutide has a half-life of approximately 6 days (based on structural analogy to other fatty-acid-acylated GLP-1 peptides and early PK modeling), approximately 5 to 6 half-lives are needed for near-complete clearance, meaning roughly 30 to 36 days of washout. Clinicians planning for women who want to conceive should stop the drug at least 2 months before a planned conception attempt to provide a safety margin, mirroring guidance for semaglutide that recommends stopping at least 2 months before planned pregnancy.

Contraception Requirements

Women of reproductive age who use triple agonists must use reliable contraception. Given the oral contraceptive absorption concern below, combined oral contraceptives alone may not be sufficient.

The oral contraceptive interaction problem. GLP-1 receptor agonists slow gastric emptying, which can reduce the peak plasma concentration (Cmax) of orally administered drugs. A pharmacokinetic study of semaglutide found that oral contraceptive Cmax was reduced by approximately 20% when co-administered. Whether this reduction is clinically significant for contraceptive failure is debated, but the FDA label for oral semaglutide recommends using a barrier method or switching to a non-oral contraceptive for 4 weeks after each dose escalation. Women using subcutaneous triple agonists should receive the same counseling as a precaution.

Recommended contraceptive options during triple-agonist therapy:

• Hormonal IUD (not affected by GI absorption changes)
• Copper IUD (no hormonal effect, not affected by GI changes)
• Etonogestrel implant (subdermal, bypasses GI tract entirely)
• Combined injectable contraceptives
• Condom plus any method above for additional protection

Women who are perimenopausal and assume they are no longer fertile should know that ovulation can occur unpredictably for years after cycles become irregular. The NAMS (The Menopause Society) recommends continuing contraception for 12 months after the final menstrual period for women over 50, and 24 months for women under 50.

Lactation

No human milk transfer data exist for retatrutide or any triple agonist. Based on the molecular weight of retatrutide (a large peptide of approximately 4,700 daltons), oral bioavailability in a nursing infant would be expected to be low because peptides are largely degraded in the neonatal gut. However, "expected to be low" is not the same as proven safe. The FDA labeling precedent for semaglutide states that it is unknown whether semaglutide is present in human milk, and the drug should be avoided during breastfeeding. The same precaution applies to triple agonists.

Postpartum women who want to use a triple agonist for weight management should complete breastfeeding before starting, or make a shared decision with their provider weighing the absence of safety data against the clinical need.

Who This Drug Class Is Right For (and Who Should Wait)

The following framework is intended to help clinicians and patients structure the "right for me?" conversation at different life stages, given that no approved drug yet exists and all use is currently investigational (clinical trial or compassionate use only).

Women Who May Be Strong Candidates Once Approved

• Women with obesity (BMI 30 or above) who have not achieved adequate response to GLP-1 or dual GIP/GLP-1 therapy
• Women with PCOS and significant metabolic comorbidity (insulin resistance, MASLD, dyslipidemia) who have plateaued on lifestyle plus metformin
• Postmenopausal women with class II or III obesity and MASLD, where the hepatic glucagon effect adds mechanistic value
• Women with type 2 diabetes, high cardiovascular risk, and obesity, pending cardiovascular outcomes trial data

Women Who Should Not Use Triple Agonists

• Pregnant women or those actively trying to conceive: contraindicated based on preclinical embryotoxicity
• Women with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2): the GLP-1 receptor agonist component carries the same boxed warning as semaglutide
• Women with a history of acute pancreatitis: glucagon receptor agonism and GLP-1 agonism both implicate pancreatic signaling pathways
• Breastfeeding women: insufficient safety data
• Women with severe hepatic impairment: glucagon receptor agonism alters hepatic glucose metabolism in ways that are not yet characterized in this population

The Perimenopause Window

Perimenopausal women occupy a unique position. Many are motivated to address the 5 to 7 pounds of visceral fat redistribution that commonly accumulates in the menopausal transition, and they may have cycled through lifestyle interventions without durable success. Triple agonists offer mechanistic appeal. The caution is bone density: glucagon receptor agonism may accelerate bone turnover at a life stage when bone loss is already accelerating due to estrogen decline. Women in this group should have a baseline DEXA scan and discuss whether concurrent menopausal hormone therapy (MHT) might be appropriate, given that MHT has demonstrated fracture protection in postmenopausal women.

Drug Interactions Specific to Women

Several interactions are particularly relevant to female physiology or to medications women commonly use.

Oral Medications With Narrow Windows

Beyond oral contraceptives, any drug that depends on consistent gastric emptying for its absorption window deserves attention. Levothyroxine, which must be taken on an empty stomach 30 to 60 minutes before food and must not be taken near other medications, may be affected by delayed gastric emptying from triple agonist use. Women with hypothyroidism, which affects approximately 5% of the US population and is disproportionately female, should take levothyroxine at a consistent time well separated from their triple-agonist injection and should recheck TSH levels 6 to 8 weeks after starting dose escalation.

Insulin and Sulfonylureas

Women with type 2 diabetes using insulin or sulfonylureas alongside a triple agonist face a clinically meaningful hypoglycemia risk because the GLP-1 and glucagon arms have opposing effects on blood glucose (GLP-1 lowers glucose; glucagon raises it), but the net effect in fasting states can be glucose reduction if insulin or sulfonylurea doses are not adjusted. Providers should reduce sulfonylurea doses by 25 to 50% at initiation and titrate based on glucose monitoring.

Hormone Therapy

No pharmacokinetic interaction studies exist between triple agonists and estradiol or progesterone formulations used in MHT. Transdermal estradiol patches, gels, and sprays bypass the GI tract entirely and would not be affected by slowed gastric emptying. Oral estradiol or oral progesterone (micronized progesterone) could theoretically be affected by altered gastric motility, but the clinical magnitude is unknown. Women on oral MHT formulations starting a triple agonist should have their symptom control reassessed at 6 to 8 weeks.

Monitoring Requirements During Triple-Agonist Therapy

Until a formal REMS establishes mandatory monitoring, the following labs reflect what clinical trial protocols and the pharmacology of the class suggest are appropriate.

| Monitoring Parameter | Timing | Rationale | |---|---|---| | Liver enzymes (AST, ALT) | Baseline, then every 3 months | Glucagon receptor activity alters hepatic metabolism | | Lipase | Baseline; with abdominal symptoms | Pancreatitis signal from GLP-1 component | | Fasting glucose and HbA1c | Baseline, 3 months, then every 6 months | Efficacy and hypoglycemia risk | | Thyroid (TSH) | Baseline; annually or with symptoms | MTC risk signal; levothyroxine dose adjustment | | DEXA bone density | Baseline in perimenopausal or postmenopausal women | Glucagon receptor effect on bone turnover | | Pregnancy test | Before starting; monthly if not using a highly effective method | Teratogenic risk | | Weight and waist circumference | Monthly | Treatment response |

The Evidence Gap: What We Do Not Know About Women

Women have been historically underrepresented in metabolic drug trials. The NIH Revitalization Act of 1993 required inclusion of women in federally funded clinical research, yet sex-disaggregated analyses remain inconsistently reported decades later.

For triple agonists specifically, the Phase 2 retatrutide trial did not publish sex-stratified efficacy or safety data. We do not know:

• Whether women and men reach comparable weight-loss endpoints at the same doses
• How the menstrual cycle modulates GI tolerability across the dose-escalation period
• Whether the bone density signal in animal models translates to women differently than men
• How triple agonists interact with hormonal contraception beyond the gastric-emptying mechanism
• Whether efficacy differs between premenopausal, perimenopausal, and postmenopausal women

This is not a minor gap. It is a gap that could affect dosing recommendations, side-effect counseling, and contraceptive management for millions of women who will eventually use this class. WomanRx will update this article as Phase 3 sex-stratified data become available.

Practical Steps for Women Considering Triple Agonists Now

1. Participate in a registered clinical trial. ClinicalTrials.gov lists open retatrutide trials that may be accessible if you meet eligibility criteria. This is the only legal path to access in the United States before approval.
2. Establish a contraception plan before enrollment. If you are in a trial, the protocol will require documentation of effective contraception. Review your options with your gynecologist before the screening visit.
3. Get baseline labs. Liver enzymes, TSH, fasting glucose, HbA1c, and a lipid panel give your provider a reference point for monitoring change.
4. Track your cycle. Logging GI symptoms, energy, and appetite relative to cycle day during dose escalation will help your clinical team understand your response and adjust timing if needed.
5. Discuss bone health if you are perimenopausal or postmenopausal. A baseline DEXA scan takes 10 to 20 minutes and gives you data that matters.

A woman with a BMI of 36, PCOS, and early MASLD who is not pregnant and uses a hormonal IUD is a reasonable candidate for a triple-agonist trial. A woman who is 38, trying to conceive in the next 6 months, and has moderately elevated weight is not, and should pursue a GLP-1 monotherapy with a documented washout plan instead.